News
3 December 2024
Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we…
3 December 2024
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is an industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title…
3 December 2024
Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant…
6 November 2024
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners…
25 April 2024
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola…
29 February 2024
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued…
8 February 2024
The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections,…
15 November 2023
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
15 November 2023
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Convincing efficacy and safety results
pHyph shows rapid symptom relief and longterm effect. Already at first day of treatment many patients see a relief in symptoms and at day 7 nearly 70% report absence of symptoms. When treated, the patients stay well and after 35 days, 85% of patients are still free from BV, compared to 54-77% with antibiotics.
90% Symptom reduction
In our most recent and largest clinical trial so far, symptom reduction was seen in 90% of patients.
Day 7
At day 7 nearly 70% of patients report abscence of symtoms
Day 25
80% are still free from BV

Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of nearly 3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*
*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.